ferric pyrophosphate citrate · Rockwell Medical Inc · NDA 206317, 208551
Triferic
1 of 3 marketed strengths has no unexpired patent or exclusivity listed; no marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7816404. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7816404 | product, use U-1656 | 17 Apr 2029 |
| US 7857977 | use U-1656 | 8 Sep 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206317 · 001 · RLD · discontinued | solution, intravenous | 27.2MG IRON/5ML (5.44MG IRON/ML) | 17 Apr 2029 |
| 206317 · 002 · RLD · discontinued | solution, intravenous | 272MG IRON/50ML (5.44MG IRON/ML) | open |
| 208551 · 001 · RLD · discontinued | powder, intravenous | 272MG IRON/PACKET | 17 Apr 2029 |